Excipients Are Not Passive
The word inactive ingredient implies that excipients do nothing. That is a convenient regulatory classification, not a pharmacological reality.
Excipients interact with APIs chemically. They compete for water. They affect the pH microenvironment within a tablet. They adsorb onto drug particles and change their surface properties. They can accelerate degradation pathways, inhibit dissolution, or modulate the release of a drug in ways that were not designed and were not tested. The excipient that looked innocuous in a pre-formulation compatibility screen can be the root cause of a stability failure three years into the programme.
Getting excipient selection right early is one of the highest-value investments in pharmaceutical formulation development. Changing an excipient late in development, when stability data has been generated and the CMC package is being assembled, is expensive and sometimes programme-threatening.
The Excipient Compatibility Screening Process
Before a formulation is finalised, the API should be assessed for compatibility with each candidate excipient under stressed conditions. The standard approach is to prepare binary mixtures of API and each excipient at a defined ratio, store them under accelerated conditions (typically 40 degrees Celsius at 75% relative humidity), and analyse them at defined timepoints for changes in appearance, moisture uptake, and chemical purity by HPLC.
A compatibility issue, visible as increased degradation in the API-excipient mixture relative to the API alone, is a signal to investigate further before including that excipient in the formulation. It is not always a reason to exclude it; sometimes the incompatibility is concentration-dependent, or is manageable with a different ratio or processing approach. But it needs to be understood.
Key Excipient Categories and Their Common Interaction Risks
| Excipient Category | Common Examples | Known Interaction Risks with APIs |
| Fillers/diluents | Lactose, microcrystalline cellulose, mannitol, calcium phosphate | Lactose Maillard reaction with primary amines; calcium phosphate may affect absorption of some drugs |
| Binders | HPMC, PVP, povidone, starch | PVP peroxide content can oxidise sensitive APIs; HPMC may affect dissolution through viscosity in some formulations |
| Disintegrants | Croscarmellose sodium, sodium starch glycolate, crospovidone | Sodium starch glycolate has residual sodium content; cross-linking agents may affect hygroscopicity |
| Lubricants | Magnesium stearate, stearic acid, sodium stearyl fumarate | Magnesium stearate can form salts with acidic APIs; over-lubrication delays dissolution; hydrophobic film on granule surface |
| Coatings | HPMC, Opadry systems, Eudragit grades | Plasticiser migration into core; coating solvent residuals; Eudragit ionic interaction with drug under specific pH conditions |
| Preservatives | Benzyl alcohol, phenol, parabens | Benzyl alcohol contraindicated in neonates; parabens estrogenic activity concern; phenol incompatible with some biologics |
| Surfactants/solubilisers | SLS, polysorbate 80, Cremophor EL | SLS promotes degradation of some APIs via radical mechanism; polysorbate oxidation products can degrade susceptible drugs |
Regulatory Considerations: Novel vs. Established Excipients
Excipients with an established history of use in approved drug products benefit from a well-understood safety and regulatory profile. Novel excipients, those not previously used or used at significantly higher levels than in approved products, require a more comprehensive safety justification in the regulatory dossier. The FDA’s inactive ingredients database is the primary reference for established excipient use in US-approved products, and the EMA’s list of excipients with established function serves an equivalent role in Europe.
For parenteral and ophthalmic products, excipient safety standards are higher than for oral products because the biological barriers that would otherwise limit systemic exposure are bypassed. An excipient that is acceptable in an oral tablet at a given concentration may not be acceptable in an injectable product at the same concentration.
The Cost of Getting It Wrong Late
Excipient changes after a stability programme has been initiated require an assessment of whether the change is significant enough to trigger new stability studies. In the worst case, a late excipient change resets the stability clock entirely, adding 12 or more months to the timeline before a regulatory filing can proceed.
Even a change that does not require new stability studies requires a change control, a regulatory assessment, and documentation that the change was justified and controlled. None of this is insurmountable, but all of it takes time that was not planned for.
Ardena’s Excipient Compatibility Expertise
Ardena’s pre-formulation team at Ghent conducts excipient compatibility screening as a standard element of the pre-formulation programme, using stressed storage conditions and HPLC stability-indicating methods. Findings are interpreted in the context of the formulation design and the intended regulatory strategy, ensuring that excipient decisions are made with full visibility of their downstream consequences.
